Candel Therapeutics, Inc. reported $195K of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $195K (to Q1 2023). Net income: −$89M, trailing twelve months to Q2 2026. Free cash flow: −$57M, trailing twelve months to Q2 2026. EPS: −$1.42, trailing twelve months to Q2 2026.

CADLCandel Therapeutics, Inc.

Healthcare

$9.66+72% 1Y

$9.66

$4.4252 weeks$13.76

CADL as reported

Candel Therapeutics, Inc. reported $195K of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed.

$195K

Revenue, trailing twelve months · to Q1 2023 · every figure below is as filed, with no scoring applied

Net income: −$89M
Net income · +300% year on year · trailing twelve months to Q2 2026
Free cash flow: −$57M
Free cash flow · +92% year on year · trailing twelve months to Q2 2026
EPS: −$1.42
EPS · +109% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for CADL, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$195K	n/a	Q1 2023 · 13 quarters behind
Net income	−$89M	+300%	Q2 2026
EPS	−$1.42	+109%	Q2 2026
Operating margin	−23115%	n/a	Q1 2023 · 13 quarters behind
Net margin	−16607%	n/a	Q1 2023 · 13 quarters behind
ROE	−53%	n/a	Q2 2026
ROA	−31%	n/a	Q2 2026
ROIC	−298%	n/a	Q2 2026
Free cash flow	−$57M	+92%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.